Order Article Reprints

Jimbu L, Mesaros O, Neaga A, Nanut AM, Tomuleasa C, Dima D, Bocsan C, Zdrenghea M. The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals. 2021; 14(11):1105. https://doi.org/10.3390/ph14111105

Jimbu, Laura, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, Ciprian Tomuleasa, Delia Dima, Corina Bocsan, and Mihnea Zdrenghea. 2021. "The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia" Pharmaceuticals 14, no. 11: 1105. https://doi.org/10.3390/ph14111105

Jimbu, L., Mesaros, O., Neaga, A., Nanut, A. M., Tomuleasa, C., Dima, D., Bocsan, C., & Zdrenghea, M. (2021). The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals, 14(11), 1105. https://doi.org/10.3390/ph14111105